Trading Higher: Aytu BioScience, Inc. (AYTU) Stock Pops Again, Will It Rise More?

Aytu BioScience, Inc. (AYTU), a Biotechnology corporation, was a bullish stock in the prior market session. Aytu BioScience, Inc. (AYTU) shares opened the market for trading at $1.3200 and closed the day at $1.4000 with increasing move of +17.65%. The increase change in Aytu BioScience, Inc. (AYTU) beat the change in the DOW for the day which gained +1.11% in prior market session.

Aytu BioScience, Inc. (AYTU) is focused on the Biotechnology sector. This stock market sector has seen some action from day traders in recent weeks. Bullish day traders of Aytu BioScience, Inc. (AYTU) will be looking for positive upcoming earnings whereas bearish day traders of Aytu BioScience, Inc. (AYTU) will be looking for negative earnings. The last time Aytu BioScience, Inc. (AYTU) had an earnings surprise was on Qtr Ending 12/19 when they reported -$0.31 compared to an estimate of -$0.34 which was a difference of $+0.03 resulting in a change of +8.82%. Current earnings estimates are to be released for Current Qtr 03/2020 on Aytu BioScience, Inc. (AYTU) and out of 1 Wall Street estimates the average is saying -$0.39. The high estimate is saying -$0.39 whereas the low estimate is saying -$0.39 and the prior year Aytu BioScience, Inc. (AYTU) announced earnings at -$0.50 a growth rate est. (year over year) of +22.00%.

The market performance of Aytu BioScience, Inc. (AYTU) has varied recently. Year to date Aytu BioScience, Inc. (AYTU)’s shares are up 43.96%. Over the past 12 weeks Aytu BioScience, Inc. (AYTU) is up 81.82% and over the last 4 weeks Aytu BioScience, Inc. (AYTU) is down -12.50%. Aytu BioScience, Inc. (AYTU) current income statement shows revenue (ttm) of $8.71M. Gross Profit is $5.12M. This puts the current EBITDA of Aytu BioScience, Inc. (AYTU) at $-15.17M.

Wall street day traders might also notice recent changes to stock analyst estimates for Aytu BioScience, Inc. (AYTU). The stock is trading with an RSI (relative strength index) of 51.39 indicating Aytu BioScience, Inc. (AYTU) is neither overbought nor oversold. Technically, AYTU’s short term support levels are around $13.75, $10.61 and $7.14 on the downside. AYTUs short term resistance levels are $33.96, $32.48 and $31.23 on the upside. The market cap of Aytu BioScience, Inc. (AYTU) is $109.778M and institutions hold 19.97% of the stock. The outstanding share count stands at 60.59M while the short float (shares short) stands at 12.99%.

Research indicates that these financial estimate changes look to be directly correlated with short-term shares prices. The day traders can look to capitalize on the basis of ranking. Aytu BioScience, Inc. (AYTU) has short term rating of Neutral (-0.20), Intermediate rating of Bullish (0.40) and long-term rating of Neutral (0.14) giving Aytu BioScience, Inc. (AYTU) an overall rating of Neutral (0.11).

The EPS growth this year on Aytu BioScience, Inc. (AYTU) is increased 77.30% and is expected to increase 91.90% next year. However, quarterly earnings (EPS) growth year over year on Aytu BioScience, Inc. (AYTU) has increased by 98.30% and quarterly revenue (Sales) growth year over year stands at 77.80%. Gross margin is detected at 74.20% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Return on equity (ttm) is -227.30%.

Recent Developments:

2020-04-23 – Biolidics Appoints Aytu Bioscience As Exclusive Distributor For Rapid Test Kits For Coronavirus.
2020-03-17 – Aytu Bioscience Announces Acceleration Of U.S. Availability Of Covid-19 Igg/Igm Rapid Test.
2020-03-12 – Sabby Management Llc Reports 9.75% Passive Stake In Aytu Bioscience.
2019-12-17 – Aytu Bioscience Files Prospectus Related To Resale Of 20 Mln Shares Of Common Stock.
2019-12-02 – Acerus Pharmaceuticals Expanded U.S. NATETSO Partnership With Aytu Bioscience Is Closed And Fully Effective As Of Dec 1.

About Company:

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction.

Leave a Comment